Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female between the ages of 20-75 years.~2. Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control.~3. Diagnosed with type 2 diabetes mellitus.~4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL~5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable).~6. All patients give written informed consent.~Exclusion Criteria:~1. A history of hypersensitivity to statins.~2. A history of rhabdomyolysis or hereditary muscle disorders.~3. Insulin-treated patients.~4. Patient with any conditions of acute or chronic pancreatitis.~5. Creatine kinase ≧3-fold upper limit of normal (ULN).~6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1.5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT ≧3-fold ULN).~7. Overt proteinuria (repeat spot urine protein \>300mg/dl by dipstick method).~8. Patients are taking cyclosporine.~9. A history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia.~10. Patients with alcohol and drug abuse in past 3 years.~11. Serious or unstable medical or psychological conditions.~12. Hypothyroidism (TSH \> 5 μIU/mL).~13. In the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
- 2 (Type: ACTIVE_COMPARATOR): 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).